These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32907626)

  • 1. Secukinumab leads to shifts from stage-based towards response-based disease clusters-comparative data from very early and established psoriatic arthritis.
    Kampylafka E; Tascilar K; Lerchen V; Linz C; Sokolova M; Zekovic A; Kleyer A; Simon D; Rech J; Sticherling M; Schett G; Hueber AJ
    Arthritis Res Ther; 2020 Sep; 22(1):207. PubMed ID: 32907626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study.
    Kampylafka E; Simon D; d'Oliveira I; Linz C; Lerchen V; Englbrecht M; Rech J; Kleyer A; Sticherling M; Schett G; Hueber AJ
    Arthritis Res Ther; 2019 Jul; 21(1):178. PubMed ID: 31349876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study.
    Kampylafka E; d'Oliveira I; Linz C; Lerchen V; Stemmler F; Simon D; Englbrecht M; Sticherling M; Rech J; Kleyer A; Schett G; Hueber AJ
    Arthritis Res Ther; 2018 Jul; 20(1):153. PubMed ID: 30053825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study.
    McInnes IB; Mease PJ; Schett G; Kirkham B; Strand V; Williams N; Fox T; Pricop L; Jugl SM; Gandhi KK;
    Arthritis Res Ther; 2018 Jun; 20(1):113. PubMed ID: 29880010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial.
    Strand V; Kaeley GS; Bergman MJ; Gladman DD; Coates LC; Sherif B; Hur P; Parikh B; Gilloteau I; Mease PJ
    Lancet Rheumatol; 2022 Mar; 4(3):e208-e219. PubMed ID: 38288937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies.
    Coates LC; Wallman JK; McGonagle D; Schett GA; McInnes IB; Mease PJ; Rasouliyan L; Quebe-Fehling E; Asquith DL; Fasth AER; Pricop L; Gaillez C
    Arthritis Res Ther; 2019 Dec; 21(1):266. PubMed ID: 31801620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations.
    Baraliakos X; Pournara E; Coates LC; Mease PJ; Jahandideh SS; Gladman DD
    Clin Exp Rheumatol; 2024 Mar; 42(3):696-701. PubMed ID: 38019168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Blachley T; Dube B; McLean RR; Kim N; Hur P; Ogdie A
    J Rheumatol; 2022 Jul; 49(7):700-706. PubMed ID: 35428716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
    Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
    J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis.
    Pournara E; Kormaksson M; Nash P; Ritchlin CT; Kirkham BW; Ligozio G; Pricop L; Ogdie A; Coates LC; Schett G; McInnes IB
    RMD Open; 2021 Nov; 7(3):. PubMed ID: 34795065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of psoriatic arthritis with secukinumab: a case series.
    Nicola S; Rolla G; Monti R; Brussino L
    J Dermatolog Treat; 2018; 29(sup1):6-8. PubMed ID: 30247936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).
    Strand V; Mease P; Gossec L; Elkayam O; van den Bosch F; Zuazo J; Pricop L; Mpofu S;
    Ann Rheum Dis; 2017 Jan; 76(1):203-207. PubMed ID: 27169431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.
    Coates LC; Mease PJ; Gladman DD; Navarra S; Bao W; Gaillez C
    RMD Open; 2023 Apr; 9(2):. PubMed ID: 37094983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
    Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
    Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the Patient-Reported Physical Function Outcome Measures in a Real-Life International Cohort of Patients With Psoriatic Arthritis.
    Leung YY; Orbai AM; de Wit M; Balanescu A; Dernis E; Soubrier M; Eder L; Smolen JS; Coates LC; Gossec L;
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):593-602. PubMed ID: 31961492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective.
    Goeree R; Chiva-Razavi S; Gunda P; Graham CN; Miles L; Nikoglou E; Jugl SM; Gladman DD
    J Med Econ; 2018 Feb; 21(2):163-173. PubMed ID: 28945143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort.
    Ruscitti P; Pantano I; Perrotta FM; Celletti E; Volpe P; Ciliento MS; Marino V; Raimondi M; Gaggiano E; Mauro D; Cataldi G; Italiano N; Di Muzio C; Navarini L; Zicolella R; Gabini M; Cipollone F; Lubrano E; Giacomelli R; Ciccia F; Cipriani P
    Clin Exp Rheumatol; 2024 Jan; 42(1):69-76. PubMed ID: 37497733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study.
    Ramonda R; Lorenzin M; Carriero A; Chimenti MS; Scarpa R; Marchesoni A; Lubrano di Scorpaniello E; Salvarani C; Cauli A; Semeraro A; Santo L; Ortolan A; Doria A; Fracassi E; Virelli G; Masia M; Fanizzi R; Visalli E; Amato G; Carletto A; Foti R;
    RMD Open; 2021 Feb; 7(1):. PubMed ID: 33593933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study.
    Coates LC; Mease PJ; Gossec L; Kirkham B; Sherif B; Gaillez C; Mpofu S; Jugl SM; Karyekar C; Gandhi KK
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1529-1535. PubMed ID: 29409133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.